46 Novel Approvals in 2025 Stress-Test CDMO Capacity Across Modalities

FDA's Center for Drug Evaluation and Research closed 2025 with 46 novel drug approvals spanning oncology, rare disease, cardiovascular, and respiratory indications -- a volume that places immediate pressure on manufacturing organisations to qualify new processes, establish supply chains for complex modalities, and maintain GMP compliance across an increasingly heterogeneous product portfolio.

The 2025 cohort reflects a pronounced shift toward biologics and targeted small molecules. Approvals include a subcutaneous co-formulation of pembrolizumab with hyaluronidase (Keytruda Qlex), an siRNA therapy for familial chylomicronemia syndrome (Redemploplozasiran), and a nucleotide combination product for the rare mitochondrial disorder thymidine kinase 2 deficiency (Kygevvi). Each modality carries distinct sterility assurance, cold-chain, and process validation requirements under 21 CFR Part 211 and ICH Q10 frameworks. CDMOs onboarding these programmes must demonstrate comparability and robust analytical method transfer before commercial launch.

• Rare disease designations dominate: approvals for Barth syndrome (Forzinity/elamipretide), TK2 deficiency (Kygevvi), familial chylomicronemia syndrome (Redemploplozasiran), and hereditary angioedema (Dawnzera) signal continued small-batch, high-potency manufacturing demands.
• Oncology remains the largest single therapeutic cluster, with approvals in AML (Komzifti/ziftomenib), HER2-mutant NSCLC (Hyrnuose/vabertinib), and metastatic breast cancer (Inluriy/imlunestrant), each requiring dedicated containment and cytotoxic handling infrastructure.
• The subcutaneous pembrolizumab approval (Keytruda Qlex) introduces device-drug combination considerations, adding design history file obligations alongside standard biologics GMP requirements.

For QA directors and plant heads, the breadth of modalities approved in a single calendar year underscores the need for flexible manufacturing platforms and pre-qualified analytical suites capable of supporting NME-specific release testing. Regulatory affairs leads should note that several 2025 approvals carry post-marketing commitments that will drive supplemental submissions through 2026 and beyond. CDER's full novel drug approvals report, including Drug Trials Snapshots for selected products, is available via FDA's Drugs@FDA database.